The Tumor Microenvironment and Inflammation Influence toxicity in patients with Large B Cell Lymphoma Treated with Axicabtagene Ciloleucel [Nanostring]. The Tumor Microenvironment and Inflammation Influence toxicity in patients with Large B Cell Lymphoma Treated with Axicabtagene Ciloleucel [Nanostring]

Tumor biopsies were taken within one month prior to CAR T infusion for evaluation of gene expression. Baseline tumor gene expression was compared between patients who went on to have severe (grade 3 or higher) neurotoxicity vs. those with non-severe neurotoxicity (grade 0 - 2). Overall design: Tumor biopsies were taken within one month of CAR T infusion in a cohort of 36 patients. RNA expression was measured by the Nanostring IO360 panel consisting of 770 genes found in the tumor microenviroment in cancer. We compared gene expression of the pre-treatment biopsy samples of patients who developed severe immune mediated toxicities ( Grade > 3 neurotoxicity) vs. those with grade 0-2 toxcities after CAR T infusion. We compared patients who went on to have a durable response (DR) to those with a non-durable response (NDR) in patients that had sufficient follow up (minimum 6 months post-CAR T infusion).